Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
|Articles|August 18, 2006
Current Options for the Treatment of Symptomatic Uterine Fibroids Video
Author(s)Charles Miller, MD
From the 34th Annual Meeting - Chicago, Illinois - November 2005
Advertisement
The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available
Advertisement
Related to this article
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.
SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Jane E. Salmon, MD, on the IMPACT trial of certolizumab pegol for adverse pregnancy outcomes in APS
2
SUID drives widening Black-White infant mortality gap since 2020
3
Protecting newborns: Obstetric and pediatric coordination on vaccines
4
What ACOG's 2026-27 respiratory virus guidance means in practice
5